Tezacaftor and ivacaftor


Entry
D11042            Mixture   Drug                                   
Name
Tezacaftor and ivacaftor;
Symdeko (TN)
Product
SYMDEKO (Vertex Pharmaceuticals Incorporated)
Component
Tezacaftor [DR:D11041], Ivacaftor [DR:D09916]
Remark
ATC code: R07AX31
Product: D11042<US>
Efficacy
Cystic fibrosis treatment
  Disease
Cystic fibrosis (CFTR F508del homozygous mutation) [DS:H00218]
Cystic fibrosis (at least one mutation in CFTR) [DS:H00218]
Target
CFTR* [HSA_VAR:1080v1] [HSA:1080] [KO:K05031]
  Pathway
hsa02010  ABC transporters
hsa04971  Gastric acid secretion
hsa04972  Pancreatic secretion
hsa04976  Bile secretion
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R07 OTHER RESPIRATORY SYSTEM PRODUCTS
   R07A OTHER RESPIRATORY SYSTEM PRODUCTS
    R07AX Other respiratory system products
     R07AX31 Ivacaftor and tezacaftor
      D11042  Tezacaftor and ivacaftor <US>
USP drug classification [BR:br08302]
 Respiratory Tract/Pulmonary Agents
  Cystic Fibrosis Agents
   Conductance Regulator Potentiator
    Tezacaftor/ Ivacaftor
     D11042  Tezacaftor and ivacaftor
Target-based classification of drugs [BR:br08310]
 Transporters
  ABC transporters
   ABCC subfamily
    CFTR* [HSA_VAR:1080v1]
     D11042  Tezacaftor and ivacaftor <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11042
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11042
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11042
Pharmacogenomic biomarkers [br08341.html]
 Germline mutations in genetic disorder treatments
  D11042
Other DBs
CAS: 1969264-35-4
PubChem: 355052576